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Abstract
Purpose: Breast cancer follow-up procedures after primary treatment are still a controversial issue. Aim of this study was to
investigate, through a web-based survey, surveillance methodologies selected by Italian oncologists in everyday clinical
practice.
Methods: Referents of Italian medical oncology units were invited to participate to the study via e-mail through the
SurveyMonkey website. Participants were asked how, in their institution, exams of disease staging and follow-up are
planned in asymptomatic women and if surveillance continues beyond the 5th year.
Results: Between February and May 2013, 125 out of 233 (53.6%) invited referents of Italian medical oncology units agreed
to participate in the survey. Ninety-seven (77.6%) referents state that modalities of breast cancer follow-up are planned
according to the risk of disease progression at diagnosis and only 12 (9.6%) oncology units apply the minimal follow-up
procedures according to international guidelines. Minimal follow-up is never applied in high risk asymptomatic women.
Ninety-eight (78.4%) oncology units continue follow-up in all patients beyond 5 years.
Conclusions: Our survey shows that 90.4% of participating Italian oncology units declare they do not apply the minimal
breast cancer follow-up procedures after primary treatment in asymptomatic women, as suggested by national and
international guidelines. Interestingly, about 80.0% of interviewed referents performs the so called ‘‘tailored follow-up’’, high
intensity for high risk, low intensity for low risk patients. There is an urgent need of randomized clinical trials able to
determine the effectiveness of risk-based follow-up modalities, their ideal frequency and persistence in time.
Citation: Natoli C, Brocco D, Sperduti I, Nuzzo A, Tinari N, et al. (2014) Breast Cancer ‘‘Tailored Follow-up’’ in Italian Oncology Units: A Web-Based Survey. PLoS
ONE 9(4): e94063. doi:10.1371/journal.pone.0094063
Editor: Syed A. Aziz, Health Canada and University of Ottawa, Canada
Received December 4, 2013; Accepted March 10, 2014; Published April 8, 2014
Copyright:  2014 Natoli et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Supported by the Consorzio Interuniversitario Nazionale per Bio-Oncologia (CINBO) and by the Gruppo Interdisciplinare Cure Oncologiche (GICO), ASL
Lanciano-Vasto-Chieti, Italy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: natoli@unich.it
" Membership of the ‘‘FOLLOW-UP’’ Study Group is provided in Appendix S1.
Introduction
Breast cancer surveillance procedures after primary treatment
are common practice in clinical oncology even if their method-
ology is still a controversial issue. The primary aim of breast
cancer follow-up is to decrease mortality and improve well-being
through early detection of second ipsi- or contralateral cancer and
local recurrences, which are potentially curable, and ascertain-
ment of symptoms suggestive of metastatic disease [1]. On the
other hand, detection of metastatic disease in asymptomatic
patients by intensive surveillance including complete blood counts,
chemistry panels, tumor markers, imaging modalities (i.e. chest
radiographs, bone scans, liver ultrasound and others) has not been
demonstrated to improve overall survival [2,3,4,5]. The secondary
aim of breast cancer follow-up is diagnosis and management of
morbidity due to adjuvant therapies [6], as well as improvement of
adherence to endocrine therapy [7,8] and assistance for psycho-
social support [5].
Since the first release of breast cancer follow-up guidelines for
management of early breast cancer patients in 1997 by the
American Society of Clinical Oncology (ASCO) [9], recommend-
ing minimal follow-up procedures (i.e. regular history taking,
clinical examination, annual surveillance mammography and
breast self-examination), this topic has been of great interest for
clinical oncologists [5,10]. ASCO breast cancer follow-up guide-
lines have been periodically updated and similar recommendations
have been adopted worldwide [11,12,13,14,15,16,17]. In Italy,
breast cancer guidelines by the Associazione Italiana di Oncologia
Medica (AIOM) recommend yearly mammography, self breast
examination, visit for history and physical examination, genetic
counseling as appropriate, gynecological visit, gynecological
echography and pap test [18]. Blood lipid profile and bone
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density scan are suggested for women treated with adjuvant
aromatase inhibitors. Other blood and imaging examinations are
not advised in asymptomatic patients. Visits should be performed
every 3–6 months for years 1–3, every 6–12 months for years 4–5,
and annually thereafter.
Even if data from randomized clinical trials and extensive
revisions of literature [2,3,4,5,19] are strongly suggestive that
intensive follow-up does not improve survival or life, in clinical
practice breast cancer patients are frequently addressed to this
modality of surveillance [8,20,21,22,23,24,25]. The great im-
provements made over the last ten years in imaging modalities and
therapies have prompted the need for more intensive procedures
than those suggested by guidelines. Still open questions are those
related to the choice of the best test to be applied, the optimal
monitoring frequency and the duration of controls after primary
surgery [11], while there is a general agreement both on annual
surveillance mammography and on tests to be applied for early
diagnosis and management of morbidity due to adjuvant
therapies.
Aim of this study has been to investigate, through a web-based
survey, which follow-up procedures are selected by Italian
oncologists in everyday clinical practice, besides those universally
accepted, such as annual mammography and adjuvant therapies
related toxicities monitoring.
Materials and Methods
Ethics statement
As the study did not involve human subjects and no patient data
were collected, ethics approval was not required.
Participants
Referents of Italian medical oncology units were invited to
participate to the study via e-mail through the SurveyMonkey
website between January and May 2013. One recall was sent out
by e-mail after one month from the first request.
Participants were asked to complete a first page with their
personal data, name, surname, institution, address, city. Then they
were required to answer if, in their institution, exams of disease
staging and follow-up are performed in a similar way for all
asymptomatic breast cancer patients or are stratified according to
the risk of disease progression, classified as low or high. If the
answer was ‘‘NO’’, they were asked if, always in asymptomatic
women, blood chemistry tests, tumor markers, chest radiograph,
liver ultrasound, bone scan, whole-body CT scan, whole-body
PET/CT scan are performed at diagnosis and at follow-up, and, if
yes, how many times/year from year 1 to 5 after primary surgical
treatment. If participants declared to perform follow-up surveil-
lance according to the risk of disease progression, they were asked
to choose which of the following factors they deem more relevant
to classify patients at high risk (more options allowed): Luminal B/
HER2-, Luminal B/HER2+, HER2+, Triple negative, pT2, pT3,
pT4, pN1, pN2, pN3 or others to be specified. Then they were
asked if they carry out blood exams, tumor markers, chest
radiography, liver ultrasound, bone scan, whole-body CT scan,
whole-body PET/CT scan at diagnosis and at follow-up in low
and high risk categories, and, if yes, how many times/year from
year 1 to 5 in both groups. Independently on how follow-up was
performed, all participants were finally asked if they continue
follow-up beyond the 5th year with 3 responses to be selected: no,
yes, only in estrogen receptor (ER) positive (+) patients.
All participating Medical Oncology Units were informed that
the results of the study were going to be published and
requirements for authorship was clearly indicated. There was no
need to protect details of the participants since these were not
patients and no personal data was collected. No patient data were
collected, so ethics approval was not required.
Statistical analysis
Data were analyzed through descriptive statistics. Differences in
proportions and comparisons between groups were performed by
using the chi-square or Fisher’s exact test when appropriate. Due
to a nonparametric distribution, data on frequency of exams
during follow-up were compared with the Friedman Test followed
by the Dunn’s Multiple Comparison Test A p value below 0.05
was retained as statistically significant. SPSS software (SPSS
version 21.0, SPSS Inc., Chicago, Illinois, USA) was used for all
statistical evaluations.
Results
Between February and May 2013, 134 out of 233 (57.5%;
SE= 3.2%) invited referents of Italian medical oncology units
agreed to participate to the e-mail survey. Among the initial 134
responses, 125 (93.3%) surveys from oncology departments widely
distributed in the Italian territory, were completed. Ninety-seven
(77.6%: SE=3.73) referents state that modalities of breast cancer
follow-up are planned according to the risk of disease progression
at diagnosis, while 25 (20.0%: SE= 3.58) perform follow-up work
similarly for all women. Overall, only 12 (9.6%: SE= 2.63)
oncology units apply the minimal follow-up procedures according
to international guidelines, 5 units only for patients in the low risk
group and 7 units for all patients, not taking into account the risk
category. Minimal follow-up is never applied in high risk
asymptomatic women. Twenty-three (18.4%: SE= 3.46) oncology
units stop surveillance at 5 years of follow-up, 98 (78.4%:
SE= 3.78) continue follow-up in all patients beyond 5 years, and
4 (3.2%) continue beyond 5 years only in hormone receptor
positive tumors.
Follow-up modalities according to the risk of disease
relapse
Oncology units performing follow-up according to the risk of
disease progression were asked to indicate which prognostic factors
they deem more relevant to stratify patients in the low and high
risk categories. As shown in Fig. 1, more than 70.0% of
respondents indicate tumor stage pT4, nodal positivity pN2-
pN3, HER2 positivity and triple negativity (i.e. the absence of
estrogen, progesteron receptor and HER2 amplification) as the
most important factors to classify patients at high risk of disease
progression. Other options, not shown, include young age, pre-
menopausal status, vascular invasion, high Ki-67 proliferation
index, BRCA positivity and familiarity.
Table 1 shows the selection of exams selected at diagnosis
according to the risk of disease progression in asymptomatic
women. Blood chemistry tests (p = 0.25), chest radiographs
(p = 0.23) and liver ultrasounds (p = 0.99) are equally selected for
both the low and the high risk groups. Tumor markers are more
frequently checked in the high risk group (p= 0.002) as well as
bone scans (p =,0.0001). Whole-body CT scan is prescribed by
33.3% of oncologists in the high risk group versus 8.3% in the low
risk group (p =,0.0001); similarly, whole-body PET/CT is
deemed relevant at diagnosis by 10.7% of oncologists for patient
in the high risk group versus 1.1% for the low risk group
(p = 0.007).
Selection of exams during follow-up according to the risk of
disease progression are also shown in Table 1. Blood chemistry
tests are chosen by more than 85% of oncologists (p = 0.16) for
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both groups of patients, while whole-body PET/CT scanning is
not prescribed by most for both categories (p = 0.08). On the other
hand, the other exams taken into account are significantly more
often selected for patients in the high risk group. However, tumor
markers, chest radiograph and liver ultrasound are selected by
more than 60% of oncologists also for the low risk group.
Follow-up modalities independently from the risk of
disease relapse
Exams at diagnosis and at follow-up selected independently
from the risk of disease relapse are shown in Table 2. Even if
numbers are small, more than 87.0% of oncologists prescribe
complete staging at diagnosis, with the exception of whole-body
CT scan and whole-body PET/CT scan. On the other hand, only
blood chemistry tests and tumor markers are selected by 60.0%
and 80.0% of oncologists during follow-up, respectively.
Frequency of exams according to the risk of disease
relapse
In the low risk group, as shown in Table 3, blood chemistry tests
and tumor markers are prescribed a median of 2 times/year in the
first 3 years of follow-up, chest radiographs and liver ultrasound 1
time/year, while bone scan, whole-body CT scan and whole-body
PET/CT scan are not taken into account. In the high risk group
(Table 3), blood chemistry tests and tumor markers are prescribed
a median of 3 times/year in the first 2 years of follow-up, and then
2 times/year. Chest radiograph is prescribed annually for five
years, liver ultrasound every six months for the first 2 years and
then annually, bone scan annually only for the first 3 years.
Whole-body CT scan and whole-body PET/CT scan are not
usually prescribed.
Frequency of exams independently of the risk of disease
relapse
Table 3 shows also that, independently on the risk of
progression, blood chemistry tests and tumor markers are
frequently prescribed 2 times/year in all patients, liver ultrasound
annually while the others are not usually prescribed.
Discussion
Our survey shows that 90.4% of Italian oncology units who
participated in the web-based questionnaire declare they do not
apply the minimal breast cancer follow-up procedures after
primary treatment in asymptomatic women, as suggested by
National and International Oncology Societies [11,14,15,18].
Although participants were almost half of the medical oncology
units present in Italy, they were uniformly distributed in the Italian
territory (as listed below) and, therefore, the survey may be
considered representative of the follow-up preferences of the
Italian oncologist. The data confirm a recent retrospective analysis
of follow-up care of breast cancer patients by Leoni et al showing
that intensive follow-up testing is a quite common clinical practice
in the Italian region Emilia-Romagna [24]. These results reflect
the never ending, 80 s dating debate on minimal versus intensive
follow-up procedures after breast cancer surgery
[2,8,9,20,21,22,23,25,26] and show that, at least in Italy, minimal
follow up procedures are prescribed by a minority of medical
oncology units [27]. Similarly, it has been recently reported the use
of non-recommended surveillance procedures for early breast
cancer patients in a Californian academic medical center [28]. On
the contrary, a higher adherence to current guidelines has been
reported for most oncologists from other countries, such as USA
[20] and Australia [29,30].
Figure 1. Tumor characteristics considered relevant to classify patients at high risk of disease progression.
doi:10.1371/journal.pone.0094063.g001
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On the other hand, it is the first time, to our knowledge, that a
high percentage of interviewed referents (about 80.0%), declares to
perform exams at diagnosis and follow-up according to the risk of
disease progression, high intensity for high risk, low intensity for
low risk patients, the so called ‘‘tailored follow-up’’. Tumor stage
pT4, pN2-pN3 and biological factors such as HER2 positivity and
triple negativity are indicated as the most relevant prognostic
factors to classify patients at high risk of disease progression. These
choices are in agreement with literature data showing that
pathological stage and intrinsic breast cancer subtypes are the
most relevant prognostic factors able to influence clinical outcome
[31,32,33,34]. Interestingly, van Hezewijk et al [8], using a web-
based 29-item questionnaire, reported that 130 respondents of
different disciplines (surgeons, medical oncologists, radiation
oncologists and nurse practitioners) identified as patients at high
risk to follow-up with a higher frequency of visits those of younger
age and with pT3-4/pN2-3 tumor, not taking into account tumor
biology, as medical oncologists did in the present study. Other
Table 1. Selection of exams at diagnosis and during follow-up according to the risk of disease progression.
At diagnosisAt At follow-up
At diagnosis
NO YES p value NO YES p value
No. (%) No. (%) No. (%) No. (%)
Blood chemistry tests
Low risk 9 (9.4) 87 (90.6) 0.25 14 (14.6) 82 (85.4) 0.16
High risk 4 (4.2) 92 (95.8) 7 (7.3) 89 (92.7)
Tumor markers
Low risk 21 (21.7) 76 (78.3) 0.002 15 (15.5) 82 (84.5) 0.03
High risk 6 (6.2) 91 (93.8) 5 (5.5) 92 (94.5)
Chest radiograph
Low risk 7 (7.3) 89 (92.7) 0.23 36 (37.5) 60 (62.5) 0.005
High risk 12 (13.0) 81 (87.0) 17 (18.3) 76 (81.7)
Liver ultrasound
Low risk 9 (9.4) 87 (90.6) 0.99 29 (30.2) 67 (69.8) ,0.0001
High risk 8 (8.6) 85 (91.4) 8 (8.6) 85 (91.4)
Bone scan
Low risk 40 (41.3) 57 (58.7) ,0.0001 69 (73.4) 25 (26.6) 0.006
High risk 3 (3.1) 94 (96.9) 50 (53.2) 44 (46.8)
Whole-body CT scan
Low risk 88 (91.7) 8 (8.3) ,0.0001 87 (93.5) 6 (6.5) ,0.0001
High risk 64 (66.7) 32 (33.3) 61 (63.6) 32 (34.4)
Whole-body PET/CT scan
Low risk 94 (98.9) 1 (1.1) 0.007 81 (96.4) 3 (3.6) 0.08
High risk 75 (89.3) 9 (10.7) 75 (89.3) 9 (10.7)
doi:10.1371/journal.pone.0094063.t001
Table 2. Selection of exams independently of the risk of disease relapse.
At diagnosis At follow-up
NO YES NO YES P value
No. (%) No. (%) No. (%) No. (%)
Blood chemistry tests 0 25 (100.0) 10 (40.0) 15 (60.0) ,0.0001
Tumor markers 3 (12.0) 22 (88.0) 5 (20.0) 20 (80.0) 0.47
Chest radiograph 3 (12.0) 22 (88.0) 18 (72.0) 7 (28.0) ,0.0001
Liver ultrasound 0 25 (100.0) 14 (56.0) 11 (44.0) ,0.001
Bone scan 1 (4.2) 24 (96.0) 20 (80.0) 5 (20.0) ,0.0001
Whole-body CT scan 19 (76.0) 6 (24.0) 25 (100.0) - 0.01
Whole-body PET/CT scan 25 (100.0) 0 25 (100.0) - -
doi:10.1371/journal.pone.0094063.t002
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studies, tailoring follow-up according to the risk of disease
progression, modulate frequency of visits and overall duration of
surveillance, instead of follow-up procedures as Italian oncologists
prefer [8,10,35,36]. In the present report tumor markers, bone
scan and whole-body CT scan are more frequently prescribed at
diagnosis and thereafter in the high risk group, while whole body
PET/CT scan is recommended only to stage disease at diagnosis.
However, tumor markers, chest radiograph and liver ultrasound
are selected by more than half of participants also for the low risk
group, and all these modes of surveillance are not recommended
by current guidelines [11,15,16,18]. The frequency of follow-up
exams is reported to be higher in the first 2–3 years in all groups
taken into account, and this is in agreement with data showing a
peak of recurrences during the first 2–3 years with a decreasing
hazard of disease progression beyond 5 years, even if estrogen
dependent tumors may recur many years after initial treatment
[37,38]. Most of participants declare to continue follow-up in all
patients, independently from risk category, beyond 5 years, in
agreement with international guidelines [9,15,16,18,26], while
very few oncology units continue surveillance beyond 5 years only
in hormone receptor positive tumors. Both ASCO and NICE
guidelines suggest frequent clinical examination in the first 3–5
years after diagnosis, but after 3 years NICE suggests to discharge
patients to general practice while ASCO suggests long-term
follow-up [11,39]. Even if there is certainly an increase in the
hazard rate of disease progression in the first 3 years after
diagnosis, this peak does not include most of new contralateral
cancers. The hazard curves for breast cancer mortality shows an
initial increase of,3%/year in the rate of distant relapses between
the 2nd and the 3rd year of surveillance, with a subsequent fall to
,2%/year which remains constant for almost 10 years [35,38]. In
contrast, potentially treatable local relapse occurs at a constant
rate of 1–1.5% per year for at least 10 years [35], thus hardly
justifying discharge at 3 years of follow-up [40,41]. Moreover,
prolonged follow-up care could offer some advantages, i.e. an
increased adherence to adjuvant endocrine therapy, known to be
higher with long-term follow-up [7,8], as well as diagnosis and
management of long-term toxicities. Late toxic effects of adjuvant
treatments may continue for many years, with some patients at
increased risk of life-threatening toxicities such as thromboembolic
disease, uterine cancer, cerebrovascular or cardiovascular events,
second malignancies and more [42,43].
Finally, we ignore which is the optimal follow-up for extended
adjuvant endocrine therapies [44,45,46], after treatment with new
biological agents [47], as well as the value of a follow-up tailored
on distinct patterns of metastatic spread depending on breast
cancer subtypes [48]. Moreover, the impact on survival of
detecting an oligometastatic disease is still unknown [49,50] and,
hopefully, the utility of an early detection of metastatic disease
suitable of cure with the ongoing molecular targeted agents or
novel therapeutics drugs [51].
Table 3. Frequency of exams during follow-up.
16 year 26 year 36 year 46 year 56 year P value
median times/year (range)
Low Risk Group
Blood chemistry test, No. 92 2 (0–4) 2 (0–4) 2 (0–3) 1 (0–2) 1 (0–2) ,0.0001
Tumor marker, No. 94 2 (0–4) 2 (0–4) 2 (0–3) 2 (0–3) 1 (0–2) ,0.0001
Chest radiograph, No. 80 1 (0–2) 1 (0–2) 1 (0–2) 0 (0–2) 0 (0–2) ,0.0001
Liver ultrasound, No. 87 1 (0–2) 1 (0–2) 1 (0–2) 1 (0–2) 1 (0–2) 0.45
Bone scan, No. 65 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–1) 0.48
Whole-body CT sca, No. 46 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–1) 0.32
Whole-body PET/CT scan, No. 46 0 0 (0–1) 0 0 (0–1) 0 0.41
High Risk Group
Blood chemistry tests, No. 92 3 (0–4) 3 (0–4) 2 (0–4) 2 (0–4) 2 (0–4) ,0.0001
Tumor markers, No. 94 3 (1–4) 3 (0–4) 2 (0–4) 2 (0–4) 2 (0–4) ,0.0001
Chest radiograph, No. 80 1 (0–2) 1 (0–2) 1 (0–2) 1 (0–2) 1 (0–2) 0.45
Liver ultrasound, No. 87 2 (0–2) 2 (0–2) 1 (0–2) 1 (0–2) 1 (0–2) ,0.0001
Bone scan, No. 65 1 (0–2) 1 (0–2) 1 (0–2) 0 (0–2) 0 (0–2) ,0.0001
Whole-body CT scan, No. 46 0.5 (0–2) 0 (0–2) 0 (0–1) 0 (0–1) 0 (0–1) ,0.0001
Whole-body PET/CT scan, No. 46 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–1) 0.57
Independently from Risk of Disease Progression
Blood chemistry tests, No. 19 2 (0–4) 2 (0–3) 2 (0–3) 1 (0–2) 1 (0–2) ,0.0001
Tumor markers, No. 20 3 (1–4) 3 (1–4) 2 (1–4) 2 (1–3) 1.5 (1–3) ,0.0001
Chest radiograph, No. 14 0.5 (0–2) 0 (0–2) 0 (0–1) 0 (0–1) 0 (0–1) 0.003
Liver ultrasound, No. 16 1 (0–2) 1 (0–2) 1 (0–2) 1 (0–2) 1 (0–2) 0.45
Bone scans, No. 12 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–1) 0.48
Whole-body CT scan, No. 10 0 0 0 0 0 -
Whole-body PET/CT scan, No. 10 0 0 0 0 0 -
No.: number of responses.
doi:10.1371/journal.pone.0094063.t003
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Further research is needed even if ongoing guidelines advise
against routine search for distant metastases, since no advantage
exists in early diagnosis and treatment [3,4,5,52]. However,
considering the plethora of novel active agents that have entered
clinical practice for metastatic breast cancer in the last years,
randomized clinical trials should be performed to determine the
comparative effectiveness of different follow-up modalities, their
ideal frequency and duration, and the development of risk-based
guidelines [16,36].
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